ISF

ISF Therapeutics was a clinical-stage biotechnology company that pioneered the development of "in situ vaccination" (ISV) for the treatment of cancer. The company's lead candidate, ISF35, was a recombinant adenovirus designed to deliver the CD154 (CD40 ligand) gene directly into a patient's tumor, effectively turning the tumor into a vaccine that stimulates a systemic immune response. This approach aimed to treat both the primary injected lesion and distant metastatic disease by activating the patient's own immune system against tumor-specific antigens. The company's innovative technology was notably licensed to MedImmune, a subsidiary of AstraZeneca, for further clinical development in various oncology indications.